CYTR News and Press, CytRx Corporation From 11/16/20

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on its results for the third quarter ended Septe...

Applauds Orphazyme’s Efforts to Pursue Approval in Europe for Arimoclomol in the Treatment of Niemann-Pick Disease Type C Notes That Arimoclomol for Niemann-Pick Disease Type C is Under the FDA’s Priority Review With a Target Action Date of March 17, 2021 ...

Applauds Orphazyme for Investing in Commercial and Other Pre-Launch Activities in Preparation of Potential FDA Approval of Arimoclomol to Treat Niemann-Pick Disease Type C Arimoclomol for Niemann-Pick Disease Type C is Under the FDA’s Priority Review With a Target...

Third-Line Cohort Added to Phase 2 Pancreatic Cancer Trial for Combination Immunotherapy That Includes Aldoxorubicin, ImmunityBio’s N-803 and NantKwest’s PD-L1 t-haNK Three Trial Sites in California and South Dakota Will Initially Enroll 298 Patients Across...

Reid’s Stage IV Pancreatic Cancer is Reportedly in “Complete Remission” After Combination Immunotherapy That Included NantKwest’s PD-L1 t-haNK, ImmunityBio’s N-803 and Aldoxorubicin ImmunityBio and NantKwest Announced in May 2020 That T...

CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today congratulated Orphazyme A/S (ORPHA.CO) (NASDAQ:ORPH) ( ...

FDA’s Priority Review Shortens Assessment Period to 6 Months, Resulting in a Target Action Date of March 17, 2021 Under PDUFA CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseas...

Highlights That Stockholders Have Voted to Re-Elect Steven A. Kriegsman and Dr. Louis Ignarro to the Board Releases New Presentation Summarizing the Company’s Strategic Priorities and Path to Delivering Long-Term Value for Stockholders CytRx Corporation (OTCQB: CYTR) (...

Accelerates Plans to Enhance its Board Composition by Committing to Add a New Independent Director Following a Professionally-Managed Search Process that Includes Stockholder Input Augments Existing Cost Reduction Efforts by Capping Management Compensation and Director Fees at Their...

Exposes Dissident as a “Frivolous Litigant” with a Highly-Questionable Background and Documented History of Poor Judgement Highlights Dissident’s Efforts to Smear CytRx and Misrepresent his Qualifications, Including by Withholding Information from Stockholders R...